MedPath

Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants

Completed
Conditions
Brain Damage, Chronic
Registration Number
NCT00544895
Lead Sponsor
Hannover Medical School
Brief Summary

NEOBRAIN brings together small and medium sized enterprises (SMEs), industry and academic groups devoted to the diagnosis, management, and neuroprotection in newborns with perinatal brain damage. The focus of NEOBRAIN is to identify strategies prevention of brain damage mainly observed in preterm newborns. (Copy from www.neobrain.eu)

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
600
Inclusion Criteria
  • Gestational age < 28 weeks
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Brain white matter damage (WMD, defined by MRI ,US, EEG)during stay in NICU and until discharge
Secondary Outcome Measures
NameTimeMethod
Developmental assessmentat 2 years of age

Trial Locations

Locations (12)

Medizinische Universität Innsbruck

🇦🇹

Innsbruck, Austria

Hôpital Robert Debré

🇫🇷

Paris, France

Charité, Campus Virchow Klinikum

🇩🇪

Berlin, Germany

Universität Duisburg-Essen

🇩🇪

Essen, Germany

Hannover Medical School

🇩🇪

Hannover, Germany

Fondazione I.R.C.C.S Ospedale Maggiore Policlinico MA.RE.

🇮🇹

Milano, Italy

Azienda Ospedaliera Universitaria Senese

🇮🇹

Siena, Italy

Wilhelmina Children's Hospital

🇳🇱

Utrecht, Netherlands

Perinatal Center

🇸🇪

Gothenburg, Sweden

University Hospital

🇸🇪

Lund, Sweden

Scroll for more (2 remaining)
Medizinische Universität Innsbruck
🇦🇹Innsbruck, Austria

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.